Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| SPRUCE BIOSCIENCES, INC.SPRB · Entity 6471 | PRESIDENT AND CFO | December 15, 2025 | December 17, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
SPRUCE BIOSCIENCES, INC.
Report date December 15, 2025 · Filed December 17, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 8,263 |
Ending reported balance
After 2025-12-15 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2025-12-15 · Exercise / conversion · Acquired 496 · Balance 8,112 F1: On December 5, 2022, the Reporting Person was granted 1,986 time-based restricted stock units ("RSUs"), subject to a 4-year vesting schedule, with 25% of the total number of RSUs vested on December 15, 2023 (the "Annual Vesting Date") and 25% of the total number of RSUs to vest in annual installments on each anniversary of the Annual Vesting Date thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2025, 496 RSUs vested, with 178 shares withheld for taxes, resulting in a net issuance of 318 shares. F2: Each RSU represents a contingent right to receive one share of common stock of the Issuer. Row 2 · 2025-12-15 · Tax withholding · Disposed 178 · Balance 7,934 F1: On December 5, 2022, the Reporting Person was granted 1,986 time-based restricted stock units ("RSUs"), subject to a 4-year vesting schedule, with 25% of the total number of RSUs vested on December 15, 2023 (the "Annual Vesting Date") and 25% of the total number of RSUs to vest in annual installments on each anniversary of the Annual Vesting Date thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2025, 496 RSUs vested, with 178 shares withheld for taxes, resulting in a net issuance of 318 shares. Row 3 · 2025-12-15 · Exercise / conversion · Acquired 513 · Balance 8,447 F3: On December 14, 2023, the Reporting Person was granted a total of 4,106 RSUs. 50% or 2,053 of the total RSUs are performance-based and all vested on December 10, 2024. An addition of 50% or 2,053 of the total RSUs are time-based. 25% of which vested on December 15, 2024, and in equal annual installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2025, 513 shares vested and 184 shares were withheld for taxes, resulting in a net issuance of 329 shares. F2: Each RSU represents a contingent right to receive one share of common stock of the Issuer. Row 4 · 2025-12-15 · Tax withholding · Disposed 184 · Balance 8,263 F3: On December 14, 2023, the Reporting Person was granted a total of 4,106 RSUs. 50% or 2,053 of the total RSUs are performance-based and all vested on December 10, 2024. An addition of 50% or 2,053 of the total RSUs are time-based. 25% of which vested on December 15, 2024, and in equal annual installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2025, 513 shares vested and 184 shares were withheld for taxes, resulting in a net issuance of 329 shares. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 497 |
Reported balance
After 2025-12-15 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-12-15 · Exercise / conversion · Disposed 496 · Balance 497 F2: Each RSU represents a contingent right to receive one share of common stock of the Issuer. F1: On December 5, 2022, the Reporting Person was granted 1,986 time-based restricted stock units ("RSUs"), subject to a 4-year vesting schedule, with 25% of the total number of RSUs vested on December 15, 2023 (the "Annual Vesting Date") and 25% of the total number of RSUs to vest in annual installments on each anniversary of the Annual Vesting Date thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2025, 496 RSUs vested, with 178 shares withheld for taxes, resulting in a net issuance of 318 shares. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 1,027 |
Reported balance
After 2025-12-15 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2025-12-15 · Exercise / conversion · Disposed 513 · Balance 1,027 F2: Each RSU represents a contingent right to receive one share of common stock of the Issuer. F3: On December 14, 2023, the Reporting Person was granted a total of 4,106 RSUs. 50% or 2,053 of the total RSUs are performance-based and all vested on December 10, 2024. An addition of 50% or 2,053 of the total RSUs are time-based. 25% of which vested on December 15, 2024, and in equal annual installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2025, 513 shares vested and 184 shares were withheld for taxes, resulting in a net issuance of 329 shares. |
Filing footnotes · ownership attribution and instrument terms
F1: On December 5, 2022, the Reporting Person was granted 1,986 time-based restricted stock units ("RSUs"), subject to a 4-year vesting schedule, with 25% of the total number of RSUs vested on December 15, 2023 (the "Annual Vesting Date") and 25% of the total number of RSUs to vest in annual installments on each anniversary of the Annual Vesting Date thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2025, 496 RSUs vested, with 178 shares withheld for taxes, resulting in a net issuance of 318 shares.
F2: Each RSU represents a contingent right to receive one share of common stock of the Issuer.
F3: On December 14, 2023, the Reporting Person was granted a total of 4,106 RSUs. 50% or 2,053 of the total RSUs are performance-based and all vested on December 10, 2024. An addition of 50% or 2,053 of the total RSUs are time-based. 25% of which vested on December 15, 2024, and in equal annual installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2025, 513 shares vested and 184 shares were withheld for taxes, resulting in a net issuance of 329 shares.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 03, 2023 Filed Jan 6, 2023 01:11 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Exercise / conversionRestricted Stock Units · Derivative | 37,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-002150 · doc4.xml · derivative · entry 4 Gharib Samir M. · CIK 0001533302 · President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 37,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of SPRB common stock. F4 · derivative.exercise_date: On December 16, 2021, the Reporting Person was granted 150,000 time-based RSUs. 25% of the RSUs vested on each of June 30, 2022 and December 31, 2022 and 50% shall vest on June 30, 2023, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). The underlying common stock of the RSUs that vested on December 31, 2022, a non-trading date, were settled on January 3, 2023. The Reporting Person was also granted 150,000 performance-based RSUs on December 16, 2021, which shall vest upon the achievement of specified performance goals. F4 · derivative.expiration_date: On December 16, 2021, the Reporting Person was granted 150,000 time-based RSUs. 25% of the RSUs vested on each of June 30, 2022 and December 31, 2022 and 50% shall vest on June 30, 2023, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). The underlying common stock of the RSUs that vested on December 31, 2022, a non-trading date, were settled on January 3, 2023. The Reporting Person was also granted 150,000 performance-based RSUs on December 16, 2021, which shall vest upon the achievement of specified performance goals. F5 · balance_after: Represents the aggregate balances of 75,000 time-based RSUs and 150,000 performance-based RSUs. Read SEC document |
| January 03, 2023 Filed Jan 6, 2023 01:11 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Tax withholdingCommon Stock | 15,293 | $1.15 | $17,586.95 |
DisclosureSEC source: 0001209191-23-002150 · doc4.xml · nonDerivative · entry 3 Gharib Samir M. · CIK 0001533302 · President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,818 F3 · shares: Represents shares withheld by the Issuer to satisfy a tax obligation realized by the Reporting Person upon the vesting and settlement of RSUs. Read SEC document |
| January 03, 2023 Filed Jan 6, 2023 01:11 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Exercise / conversionCommon Stock | 37,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-002150 · doc4.xml · nonDerivative · entry 2 Gharib Samir M. · CIK 0001533302 · President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,111 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of SPRB common stock. Read SEC document |
| December 30, 2022 Filed Jan 6, 2023 01:11 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | GrantCommon Stock | 1 | $0.93 | $0.93 |
DisclosureSEC source: 0001209191-23-002150 · doc4.xml · nonDerivative · entry 1 Gharib Samir M. · CIK 0001533302 · President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,611 F1 · shares: Shares acquired by the Reporting Person pursuant to the Issuer's 2020 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). The Reporting Person acquired the maximum shares allowable pursuant to Section 423 of the Internal Revenue Code. Read SEC document |
| December 05, 2022 Filed Dec 8, 2022 01:04 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | GrantRestricted Stock Units · Derivative | 149,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-060276 · doc4.xml · derivative · entry 1 Gharib Samir M. · CIK 0001533302 · President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,000 Underlying: Common Stock · 149,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of the Issuer. F2 · derivative.exercise_date: The RSUs vest over four years. 25% of the RSUs will vest on December 15, 2023 (the "Annual Vesting Date"), and 25% of the total number of RSUs will vest in annual installments on each anniversary of the Annual Vesting Date thereafter, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). F2 · derivative.expiration_date: The RSUs vest over four years. 25% of the RSUs will vest on December 15, 2023 (the "Annual Vesting Date"), and 25% of the total number of RSUs will vest in annual installments on each anniversary of the Annual Vesting Date thereafter, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). Read SEC document |
| June 30, 2022 Filed Jul 5, 2022 20:04 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Exercise / conversionRestricted Stock Units · Derivative | 37,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-040557 · doc4.xml · derivative · entry 4 Gharib Samir M. · CIK 0001533302 · President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 262,500 Underlying: Common Stock · 37,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of SPRB common stock. F4 · derivative.exercise_date: On December 16, 2021, the Reporting Person was granted 150,000 time-based RSUs. 25% of the RSUs vested on June 30, 2022, 25% shall vest on December 31, 2022 and 50% shall vest on June 30, 2023, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). The Reporting Person was also granted 150,000 performance-based RSUs, which shall vest upon the achievement of specified performance goals. F4 · derivative.expiration_date: On December 16, 2021, the Reporting Person was granted 150,000 time-based RSUs. 25% of the RSUs vested on June 30, 2022, 25% shall vest on December 31, 2022 and 50% shall vest on June 30, 2023, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). The Reporting Person was also granted 150,000 performance-based RSUs, which shall vest upon the achievement of specified performance goals. F5 · balance_after: Represents the aggregate balances of 112,500 time-based RSUs and 150,000 performance-based RSUs. Read SEC document |
| June 30, 2022 Filed Jul 5, 2022 20:04 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Tax withholdingCommon Stock | 12,968 | $1.74 | $22,564.32 |
DisclosureSEC source: 0001209191-22-040557 · doc4.xml · nonDerivative · entry 3 Gharib Samir M. · CIK 0001533302 · President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,610 F3 · shares: Represents shares withheld by the Issuer to satisfy a tax obligation realized by the Reporting Person upon the vesting and settlement of RSUs. Read SEC document |
| June 30, 2022 Filed Jul 5, 2022 20:04 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | GrantCommon Stock | 5,446 | $1.48 | $8,054.63 |
DisclosureSEC source: 0001209191-22-040557 · doc4.xml · nonDerivative · entry 2 Gharib Samir M. · CIK 0001533302 · President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,578 F2 · shares: Shares acquired by the Reporting Person pursuant to the Issuer's 2020 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). The Reporting Person acquired the maximum shares allowable pursuant to Section 423 of the Internal Revenue Code. Read SEC document |
| June 30, 2022 Filed Jul 5, 2022 20:04 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Exercise / conversionCommon Stock | 37,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-040557 · doc4.xml · nonDerivative · entry 1 Gharib Samir M. · CIK 0001533302 · President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,132 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of SPRB common stock. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 21:00 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | GrantEmployee Stock Option (right to buy) · Derivative | 70,000 | $0.00 Strike: $4.59 | $0.00 |
DisclosureSEC source: 0001209191-22-001621 · doc4.xml · derivative · entry 2 Gharib Samir M. · CIK 0001533302 · President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2032-01-02 F2 · derivative.exercise_date: 1/48th of the shares vest on a monthly basis from January 3, 2022, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). Read SEC document |
| December 31, 2021 Filed Jan 5, 2022 21:00 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | OtherCommon Stock | 2,220 | $3.79 | $8,416.02 |
DisclosureSEC source: 0001209191-22-001621 · doc4.xml · nonDerivative · entry 1 Gharib Samir M. · CIK 0001533302 · President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,632 F1 · shares: Shares acquired by the Reporting Person pursuant to the Issuer's 2020 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). The Reporting Person acquired the maximum shares allowable pursuant to Section 423 of the Internal Revenue Code. Read SEC document |
| December 16, 2021 Filed Dec 21, 2021 02:10 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | GrantRestricted Stock Units · Derivative | 300,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-070719 · doc4.xml · derivative · entry 2 Gharib Samir M. · CIK 0001533302 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of SPRB common stock. F3 · derivative.exercise_date: 150,000 of the restricted stock units shall vest 25% on June 30, 2022, 25% shall vest on December 31, 2022 and 50% shall vest on June 30, 2023, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). F4 · derivative.exercise_date: 150,000 of the restricted stock units shall vest upon the achievement of specified performance goals. F3 · derivative.expiration_date: 150,000 of the restricted stock units shall vest 25% on June 30, 2022, 25% shall vest on December 31, 2022 and 50% shall vest on June 30, 2023, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). F4 · derivative.expiration_date: 150,000 of the restricted stock units shall vest upon the achievement of specified performance goals. Read SEC document |
| December 16, 2021 Filed Dec 21, 2021 02:10 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | GrantEmployee Stock Option (right to buy) · Derivative | 145,000 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001209191-21-070719 · doc4.xml · derivative · entry 1 Gharib Samir M. · CIK 0001533302 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,000 Underlying: Common Stock · 145,000 shares Expires 2031-12-15 F1 · derivative.exercise_date: 1/48th of the shares vest on a monthly basis from December 16, 2021, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). Read SEC document |
| June 30, 2021 Filed Jul 6, 2021 20:11 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | OtherCommon Stock | 1,412 | $9.53 | $13,454.24 |
DisclosureSEC source: 0001209191-21-045416 · doc4.xml · nonDerivative · entry 1 Gharib Samir M. · CIK 0001533302 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,412 F1 · shares: Shares acquired by Mr. Gharib pursuant to the Issuer's 2020 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| January 28, 2021 Filed Jan 30, 2021 02:48 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | GrantStock Option (Right to Buy) · Derivative | 55,000 | $0.00 Strike: $20.08 | $0.00 |
DisclosureSEC source: 0001209191-21-006374 · doc4.xml · derivative · entry 1 Gharib Samir M. · CIK 0001533302 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2031-01-27 F1 · derivative.exercise_date: The shares vest over a four-year period commencing January 28, 2021, with 1/48th of the shares vesting on a monthly basis. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.